DUBLIN, April 25, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN) today announced that it has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) for TrueTear ™ ...

LAKE CHARLES, LA (KPLC) - A life-changing device is helping people with severe dry eye see and feel better. Melanie Kratzer was diagnosed with nine autoimmune diseases by the age of 30. The medication ...

Here are three things to know. 1. The handheld device uses electrical stimulation to temporarily increase tear production in adult patients with dry eye. 2. Patients insert the device, which comes ...

TrueTear, officially launched just months ago at the American Society of Cataract and Refractive Surgery meeting, is the first-ever neurostimulation device in eye care, offering a drug-free, drop-free ...

WORCESTER - Dry eye disease, a condition typically characterized by scratchy, irritated eyes and blurry vision, or even unusually watery eyes, is extremely common, yet often untreated. Faculty members ...

Earlier this year, Allergan launched a unique device called TrueTear(R) that helps patients produce more of their own natural tears. TrueTear(R) is an intranasal tear neurostimulator that works by ...

Safety and efficacy of the TrueTear device were demonstrated in two clinical studies in a total of 145 individuals with aqueous deficient dry eye. Allergan has been granted marketing authorization ...

The TrueTear device is a noninvasive, drug-free way to temporarily increase tear production in adult patients. (Allergan) () The FDA granted Allergan marketing authorization for its intranasal tear ...

Please provide your email address to receive an email when new articles are posted on . Allergan announced the official launch of TrueTear, an FDA-approved device developed to temporarily increase ...

Allergan PLC received Food and Drug Administration approval for TrueTear Intranasal Tear Neurostimular, a device that temporarily increases tear production via electrical stimulation. The company said ...